OMER

11.84

4.04% 0.46

Pre-mercato: 11.85 0.010 +0.08%

Omeros Corporation (OMER)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$11.38

Aprire:

$11.48

Volume 24 ore:

774.77K

Relative Volume:

0.58

Capitalizzazione di mercato:

$852.43M

Reddito:

Utile/perdita netta:

$-4.81M

Rapporto P/E:

-23.69

EPS:

-0.4998

Flusso di cassa netto:

$-122.54M

1 W Prestazione:

+7.83%

1M Prestazione:

+5.81%

6M Prestazione:

+188.78%

1 anno Prestazione:

+69.38%

Intervallo 1D:

$11.46

$11.84

Intervallo di 1 settimana:

$10.93

$12.02

Portata 52W:

$2.95

$17.65

Omeros Corporation Stock (OMER) Company Profile

Nome

Omeros Corporation

Settore

Healthcare (1110)

Industria

Biotechnology (622)

Telefono

206-676-5000

Indirizzo

201 ELLIOTT AVENUE WEST, SEATTLE, WA

Dipendente

175

Cinguettio

@OmerosCorp

Prossima data di guadagno

2026-03-31

Ultimi documenti SEC

OMER's Discussions on Twitter

Compare OMER vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
OMER Omeros Corporation	11.84	827.24M	0	-4.81M	-122.54M	-0.4998
VRTX Vertex Pharmaceuticals Inc	444.28	110.97B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	755.51	79.17B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	828.35	49.73B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	339.41	42.98B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	310.00	34.37B	5.36B	287.73M	924.18M	2.5229

Omeros Corporation Stock (OMER) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-06-10	Iniziato	H.C. Wainwright	Buy
2024-12-23	Iniziato	D. Boral Capital	Buy
2024-11-14	Iniziato	Rodman & Renshaw	Buy
2022-12-08	Downgrade	UBS	Buy → Neutral
2022-11-08	Downgrade	BofA Securities	Neutral → Underperform
2022-06-08	Downgrade	BofA Securities	Buy → Neutral
2021-10-08	Downgrade	JP Morgan	Neutral → Underweight
2021-10-01	Downgrade	Maxim Group	Buy → Hold
2021-10-01	Downgrade	Wedbush	Neutral → Underperform
2021-09-27	Iniziato	JP Morgan	Neutral
2021-02-01	Iniziato	UBS	Buy
2020-10-20	Iniziato	BofA Securities	Buy
2020-08-21	Reiterato	H.C. Wainwright	Buy
2020-08-14	Reiterato	Maxim Group	Buy
2019-05-06	Iniziato	Cantor Fitzgerald	Overweight
2018-07-12	Iniziato	Seaport Global Securities	Buy
2018-03-23	Downgrade	Wedbush	Outperform → Neutral
2018-03-05	Downgrade	Needham	Buy → Hold
2017-11-08	Iniziato	H.C. Wainwright	Buy
2017-05-11	Downgrade	Cantor Fitzgerald	Buy → Neutral
2017-03-17	Reiterato	Maxim Group	Buy
2017-03-17	Reiterato	Needham	Buy
2016-11-16	Reiterato	Wedbush	Outperform
2016-11-10	Reiterato	Needham	Buy
2016-08-10	Reiterato	Maxim Group	Buy
2016-06-03	Iniziato	Cantor Fitzgerald	Buy
2016-03-02	Reiterato	Needham	Buy
2016-02-29	Reiterato	Wedbush	Outperform
2015-11-11	Reiterato	Needham	Buy
2015-08-18	Reiterato	WBB Securities	Strong Buy
2015-08-10	Iniziato	ROTH Capital	Buy

Mostra tutto

Omeros Corporation Borsa (OMER) Ultime notizie

Apr 13, 2026

Published on: 2026-04-14 03:02:37 - baoquankhu1.vn

Apr 13, 2026

OMER stock surges 5% after hours on Novo Nordisk deal windfall and drug launch optimism - MSN

Apr 13, 2026

Apr 12, 2026

Omeros rises as Novo deal boosts Q4 earnings - MSN

Apr 12, 2026

Omeros Corporation (NASDAQ:OMER) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Apr 12, 2026

Apr 10, 2026

Does Omeros (OMER) Have the Potential to Rally 266.67% as Wall Street Analysts Expect? - Yahoo Finance

Apr 10, 2026

OMER News | OMEROS CORP (NASDAQ:OMER) - ChartMill

Apr 10, 2026

Earnings Risk: What is the long term forecast for Omeros Corporation stock2026 Technicals & Weekly Momentum Picks - baoquankhu1.vn

Apr 10, 2026

Apr 08, 2026

Omeros expects YARTEMLEA to be financially self-sustaining in 2026 and targets positive cash flow in 2027 - MSN

Apr 08, 2026